Eikon Therapeutics, Inc. Common Stock (EIKN) Stock
Fundamentals
Source: third-party data provider, as of October 15, 2026
Compare with EIKN
Recent news

Eikon Therapeutics Eyes Safer PARP1 Cancer Treatments With EIK1003, EIK1004
Eikon Therapeutics Eyes Safer PARP1 Cancer Treatments With EIK1003, EIK1004
EIKN

Eikon Therapeutics valued at $860 million in Nasdaq debut
Eikon Therapeutics valued at $860 million in Nasdaq debut
EIKN

Perlmutter-backed Eikon Therapeutics raises $381.2 million in IPO
Perlmutter-backed Eikon Therapeutics raises $381.2 million in IPO
EIKN

Eikon Therapeutics targets $908 million valuation in US IPO
Eikon Therapeutics targets $908 million valuation in US IPO
EIKN
Technical indicators
- RSI 14
- 33.34
- MACD 12/26/9
- -0.69
- EMA 9 of MACD
- -0.68
- MACD histogram
- -0.01
- SMA 50
- $9.45
- Price below SMA 50
- EMA 50
- $8.90
- Price below EMA 50
Calculated by Gotrade from daily closing prices, as of October 14, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Sell
Based on 1 analyst rating
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
No data available
Debt & Balance Sheet
No data available
Revenue to Profit
No data available
Earnings
No data available
Source: third-party data provider
Latest news

Eikon Therapeutics Eyes Safer PARP1 Cancer Treatments With EIK1003, EIK1004
Eikon Therapeutics Eyes Safer PARP1 Cancer Treatments With EIK1003, EIK1004
EIKN

Eikon Therapeutics valued at $860 million in Nasdaq debut
Eikon Therapeutics valued at $860 million in Nasdaq debut
EIKN

Perlmutter-backed Eikon Therapeutics raises $381.2 million in IPO
Perlmutter-backed Eikon Therapeutics raises $381.2 million in IPO
EIKN

Eikon Therapeutics targets $908 million valuation in US IPO
Eikon Therapeutics targets $908 million valuation in US IPO
EIKN

Biopharmaceutical firm Eikon Therapeutics files for US IPO
Biopharmaceutical firm Eikon Therapeutics files for US IPO
EIKN
About Eikon Therapeutics, Inc. Common Stock
The company is a late-stage clinical biopharmaceutical organization focused on building a global, fully integrated platform to develop innovative medicines that address serious unmet medical needs. It is led by internationally recognized drug development leaders Dr. Roger M. Perlmutter, M.D., Ph.D., and Dr. Roy Baynes, M.D., Ph.D. The company’s vision is to become a generational leader by intentionally integrating traditional biological research with advanced engineering capabilities to accelerate the development of higher-quality medicines. Its initial therapeutic focus is oncology, with a pipeline of drug candidates targeting areas of significant unmet need across large patient populations.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Roger M. Perlmutter M.D., Ph.D. | Chairman, President & CEO | 1952 |
| Mr. Michael A. Klobuchar | Chief Operating Officer | 1976 |
| Dr. Alfred Lloyd Bowie Jr., Ph.D. | Treasurer & CFO | 1982 |
| Dr. Roy D. Baynes FACP, M.D., Ph.D. | Executive VP & Chief Medical Officer | 1955 |
| Dr. Robert Tjian Ph.D. | Co-Founder & Member of Scientific Advisory Board | 1949 |
| Dr. Eric Betzig Ph.D. | Co-Founder & Member of Scientific Advisory Board | — |
| Mr. Russ Berman | Chief Technology Officer | — |
| Dr. Ching-Pin Chang M.D., Ph.D. | Executive VP & Chief Scientific Officer | — |
| Mr. Benjamin Bruno Thorner | Secretary, General Counsel & Chief Business Officer | 1971 |
| Ms. Barbara Howes M.B.A. | Chief People Officer | 1965 |
Fundamentals
Valuation
Earnings Per Share
Income Statement
Dividend
Source: third-party data provider, as of October 15, 2026
Technical indicators
- RSI 14
- 33.34
- MACD 12/26/9
- -0.69
- EMA 9 of MACD
- -0.68
- MACD histogram
- -0.01
- SMA 50
- $9.45
- Price below SMA 50
- EMA 50
- $8.90
- Price below EMA 50
Calculated by Gotrade from daily closing prices, as of October 14, 2026. Technical data, not a recommendation.
Analyst views
1 analyst rating
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $4.00
- Average
- $4.00
- High
- $4.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -8.1 | -28.9 | -4.6 | +12.0 | +20.9 | -24.8 | +14.3 | -26.1 | -5.4 |



